Provision of fully informed consent prior to study specific procedures.
Patients must be >= 19 years of age
RET fusion positive or FGFR2 fusion/other FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy.
ECOG Performance status0-2
Have measurable or evaluated disease based on RECIST 1.1 as determined by investigator.
Absolute neutrophil count >= 1.5 x 109/L, Hemoglobin >= 9g/dL, Platelets>=100 x 109/L Bilirubin <= 1.5 x upper limit of normal AST/ALT <= 2.5 X upper limit of normal(5.0 x upper limit of normal, for subject with liver metastases) Creatinine<= 1.5 X UNL
Patients of child-bearing potential should be using adequate contraceptive measures should not be breast feeding and must have a negative pregnancy test prior to start of dosing
Adequate heart function

NCT02691793_inc_T2
Person
age
NCT02691793_inc_T3
Value
>= 19 years
NCT02691793_inc_T4
Measurement
RET fusion
NCT02691793_inc_T5
Value
positive
NCT02691793_inc_T6
Qualifier
FGFR2 fusion
NCT02691793_inc_T7
Qualifier
FGFR mutation
NCT02691793_inc_T8
Qualifier
Refractory
NCT02691793_inc_T9
Condition
solid tumor
NCT02691793_inc_T10
Scope
FGFR2 fusion/other FGFR mutation
NCT02691793_inc_T11
Qualifier
sensitivity
NCT02691793_inc_T12
Drug
Sunitinib
NCT02691793_inc_T14
Measurement
ECOG Performance status
NCT02691793_inc_T15
Value
0-2
NCT02691793_inc_T17
Measurement
Absolute neutrophil count
NCT02691793_inc_T18
Value
>= 1.5 x 109/L
NCT02691793_inc_T19
Measurement
Hemoglobin
NCT02691793_inc_T20
Value
>= 9g/dL,
NCT02691793_inc_T21
Measurement
Platelets
NCT02691793_inc_T22
Value
>=100 x 109/L
NCT02691793_inc_T23
Measurement
Bilirubin
NCT02691793_inc_T24
Value
<= 1.5 x upper limit of normal
NCT02691793_inc_T25
Measurement
AST
NCT02691793_inc_T26
Measurement
ALT
NCT02691793_inc_T27
Value
<= 2.5 X upper limit of normal(
NCT02691793_inc_T28
Condition
liver metastases
NCT02691793_inc_T29
Value
5.0 x upper limit of normal
NCT02691793_inc_T30
Measurement
Creatinine
NCT02691793_inc_T31
Value
<= 1.5 X UNL
NCT02691793_inc_T32
Measurement
AST
NCT02691793_inc_T33
Measurement
ALT
NCT02691793_inc_T34
Condition
Adequate heart function
NCT02691793_inc_T35
Measurement
heart function
NCT02691793_inc_T36
Value
Adequate
NCT02691793_inc_T37
Observation
child-bearing potential
NCT02691793_inc_T38
Procedure
adequate contraceptive measures
NCT02691793_inc_T39
Negation
not be
NCT02691793_inc_T40
Condition
breast feeding
NCT02691793_inc_T41
Value
negative
NCT02691793_inc_T42
Measurement
pregnancy test
NCT02691793_inc_T43
Temporal
prior to start of dosing
NCT02691793_inc_T44
Reference_point
start of dosing
NCT02691793_inc_T45
Scope
adequate contraceptive measures should not be breast feeding and must have a negative pregnancy test prior to start of dosing